Skip to main content
Erschienen in: Annals of Nuclear Medicine 9/2020

13.06.2020 | Original Article

Feasibility study of a PET-only amyloid quantification method: a comparison with visual interpretation

verfasst von: Natsumi Shimokawa, Go Akamatsu, Miyako Kadosaki, Masayuki Sasaki

Erschienen in: Annals of Nuclear Medicine | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

Visual evaluation is the standard for amyloid positron emission tomography (PET) examination, though the result depends upon the physician’s subjective review of the images. Therefore, it is expected that objective quantitative evaluation is useful for image interpretation. In this study, we examined the usefulness of the quantitative evaluation of amyloid PET using a PET-only quantification method in comparison with visual evaluation.

Methods

In this study we retrospectively investigated a total of 166 individuals, including 58 cognitively normal controls, 62 individuals with mild cognitive impairment, and 46 individuals with early Alzheimer’s disease. They underwent 11C-Pittsburgh compound-B (PiB) PET examination through the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI). Amyloid accumulation in cerebral cortices was assessed using visual and quantitative methods. The quantitative evaluation was performed using the adaptive template method and empirically PiB-prone region of interest, and the standardized uptake value ratio (SUVR) in each area was obtained.

Results

Visual evaluation and SUVR were significantly correlated in the cerebral cortices (ρ = 0.85–0.87; p < 0.05). In visual evaluation, sensitivity, specificity, and accuracy were 78%, 76%, and 77%, respectively. Meanwhile, for quantitative evaluation, sensitivity, specificity, and accuracy were 77%, 79%, and 78% in mean cortical SUVR (mcSUVR) and 79%, 79%, and 79% in maximum SUVR (maxSUVR), respectively.

Conclusion

The PET-only quantification method provided a concordant result with visual evaluation and was considered useful for amyloid PET.
Literatur
1.
Zurück zum Zitat Ninomiya T. Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD). Brain Nerve. 2017;69:763–9.PubMed Ninomiya T. Japan Prospective Studies Collaboration for Aging and Dementia (JPSC-AD). Brain Nerve. 2017;69:763–9.PubMed
3.
Zurück zum Zitat Akatsu H, Takahashi M, Matsukawa N, Ishikawa Y, Kondo N, Sato T, et al. Subtype analysis of neuropathologically diagnosed patients in a Japanese geriatric hospital. J Neurol Sci. 2002;196:63–9.CrossRefPubMed Akatsu H, Takahashi M, Matsukawa N, Ishikawa Y, Kondo N, Sato T, et al. Subtype analysis of neuropathologically diagnosed patients in a Japanese geriatric hospital. J Neurol Sci. 2002;196:63–9.CrossRefPubMed
5.
Zurück zum Zitat Bateman R, Xiong C, Benzinger T, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795–804.CrossRefPubMedPubMedCentral Bateman R, Xiong C, Benzinger T, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795–804.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78.CrossRefPubMed Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78.CrossRefPubMed
7.
Zurück zum Zitat Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275–83.CrossRefPubMedPubMedCentral Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275–83.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287–94.CrossRefPubMed Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72:287–94.CrossRefPubMed
9.
Zurück zum Zitat Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid plaques in Alzheimer disease: Phase 3 study. Alzheimers Dement. 2015;11:964–74.CrossRefPubMed Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, et al. Florbetaben PET imaging to detect amyloid plaques in Alzheimer disease: Phase 3 study. Alzheimers Dement. 2015;11:964–74.CrossRefPubMed
10.
Zurück zum Zitat Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959–72.PubMed Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959–72.PubMed
11.
Zurück zum Zitat Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363–72.CrossRefPubMed Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363–72.CrossRefPubMed
12.
Zurück zum Zitat Akamatsu G, Ikari Y, Ohnishi A, Nishida H, Aita K, Sasaki M, et al. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI. Phys Med Biol. 2016;61:5768–80.CrossRefPubMed Akamatsu G, Ikari Y, Ohnishi A, Nishida H, Aita K, Sasaki M, et al. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI. Phys Med Biol. 2016;61:5768–80.CrossRefPubMed
13.
Zurück zum Zitat Yamane T, Ishii K, Sakata M, Ikari Y, Nishio T, Ishii K, et al. Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging. 2017;44:850–7.CrossRefPubMed Yamane T, Ishii K, Sakata M, Ikari Y, Nishio T, Ishii K, et al. Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging. 2017;44:850–7.CrossRefPubMed
14.
Zurück zum Zitat Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Macaulay SL, et al. MR-less surface-based amyloid assessment based on 11C PiB PET. PLoS ONE. 2014;9:e84777.CrossRefPubMedPubMedCentral Zhou L, Salvado O, Dore V, Bourgeat P, Raniga P, Macaulay SL, et al. MR-less surface-based amyloid assessment based on 11C PiB PET. PLoS ONE. 2014;9:e84777.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay SL, Martins R, et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging. 2015;36(Suppl 1):S159–S166166.CrossRefPubMed Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay SL, Martins R, et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging. 2015;36(Suppl 1):S159–S166166.CrossRefPubMed
16.
Zurück zum Zitat Su Y, D'Angelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, et al. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS ONE. 2013;8:e73377.CrossRefPubMedPubMedCentral Su Y, D'Angelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, et al. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS ONE. 2013;8:e73377.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Saint-Aubert L, Nemmi F, Péran P, Barbeau EJ, Payoux P, Chollet F, et al. Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Eur J Nucl Med Mol Imaging. 2014;41:836–43.CrossRefPubMed Saint-Aubert L, Nemmi F, Péran P, Barbeau EJ, Payoux P, Chollet F, et al. Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Eur J Nucl Med Mol Imaging. 2014;41:836–43.CrossRefPubMed
18.
Zurück zum Zitat Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, et al. Japanese and North American Alzheimer’s Disease Neuroimaging Initiative studies: harmonization for international trials. Alzheimers Dement. 2018;14:1077–87.CrossRefPubMed Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, et al. Japanese and North American Alzheimer’s Disease Neuroimaging Initiative studies: harmonization for international trials. Alzheimers Dement. 2018;14:1077–87.CrossRefPubMed
19.
Zurück zum Zitat Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med. 2014;55:1623–8.CrossRefPubMed Thurfjell L, Lilja J, Lundqvist R, Buckley C, Smith A, Vandenberghe R, et al. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads. J Nucl Med. 2014;55:1623–8.CrossRefPubMed
20.
Zurück zum Zitat Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C-PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain. 2008;131:665–80.CrossRefPubMedPubMedCentral Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, et al. 11C-PiB and structural MRI provide complementary information in imaging of Alzheimer’s disease and amnestic mild cognitive impairment. Brain. 2008;131:665–80.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Vandenberghe R, Laere KV, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29.CrossRefPubMed Vandenberghe R, Laere KV, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29.CrossRefPubMed
Metadaten
Titel
Feasibility study of a PET-only amyloid quantification method: a comparison with visual interpretation
verfasst von
Natsumi Shimokawa
Go Akamatsu
Miyako Kadosaki
Masayuki Sasaki
Publikationsdatum
13.06.2020
Verlag
Springer Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 9/2020
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-020-01486-3

Weitere Artikel der Ausgabe 9/2020

Annals of Nuclear Medicine 9/2020 Zur Ausgabe